BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Key Highlights
- ➤BioNTech will present 16 oncology abstracts spanning ten tumor types at ESMO 2026.
- ➤ROSETTA Lung-107 will report first Phase 2 data for pumitamig plus docetaxel in second-line metastatic NSCLC.
- ➤Pumitamig plus chemotherapy showed generally consistent systemic efficacy with and without brain metastases in SCLC and TNBC.
- ➤Pumitamig plus FOLFIRI showed encouraging preliminary activity and manageable safety in second-line neuroendocrine neoplasms.
- ➤Pumitamig plus elfetabart drozuntecan showed preliminary activity across advanced solid tumors with minimal overlapping toxicities.
Expert Statements
Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech
“Sixteen abstracts spanning ten tumor types – this is our significant data presence at this year’s ESMO. It demonstrates momentum for our late-stage oncology pipeline across strategic key assets and tumor areas such as lung and breast cancer.”
Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech
“For our PD-L1xVEGF immunomodulator pumitamig, we will be sharing new data that highlights its pan-tumor potential, including in challenging treatment settings where patients still show limited benefit from current standard of care therapies.”
Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech
“Our goal is to establish pumitamig as a potential backbone for future combination regimens across multiple tumor types, including novel-novel treatment combinations.”
Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech
“At this year’s conference, we will showcase the potential of this approach in two presentations featuring ADC combinations, aimed to further enhance outcomes for patients.”
* Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic non-small cell lung cancer following prior immunotherapy plus chemotherapy * Global Phase 2 data for pumitamig plus elfetabart drozuntecan, a B7-H3-targeting antibody-drug conjugate, expand the body of evidence for this novel-novel combination in multiple advanced solid tumors * Updates from across the pumitamig clinical development program underscore its pan-tumor potential, including in lung and breast cancer patients with brain metastases and patients with neuroendocrine neoplasms MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company’s tumor focus areas, including lung and breast cancer, at the European Society for Medical Oncology (“ESMO”) 2026 Congress held in Madrid, Spain, from October 23–27, 2026.
Get started
Create a free account to read the full story.